Trademark: 87379490
Word
GLAUPREXA
Status
Dead
Status Code
606
Status Date
Monday, January 4, 2021
Serial Number
87379490
Mark Type
4000
Filing Date
Tuesday, March 21, 2017
Published for Opposition
Tuesday, June 6, 2017
Abandoned Date
Monday, January 4, 2021

Trademark Owner History
Allergan, Inc. - Owner At Publication

Classifications
5 Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Events
Jan 4, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Jan 4, 2021
Abandonment - No Use Statement Filed
Apr 16, 2020
Notice Of Approval Of Extension Request E-Mailed
Apr 15, 2020
Extension 5 Granted
Apr 13, 2020
Extension 5 Filed
Apr 15, 2020
Case Assigned To Intent To Use Paralegal
Apr 13, 2020
Teas Extension Received
Nov 8, 2019
Notice Of Approval Of Extension Request E-Mailed
Nov 6, 2019
Extension 4 Granted
Nov 6, 2019
Extension 4 Filed
Nov 6, 2019
Teas Extension Received
Mar 14, 2019
Notice Of Approval Of Extension Request E-Mailed
Mar 12, 2019
Extension 3 Granted
Mar 12, 2019
Extension 3 Filed
Mar 12, 2019
Teas Extension Received
Oct 30, 2018
Notice Of Approval Of Extension Request E-Mailed
Oct 26, 2018
Extension 2 Granted
Oct 26, 2018
Extension 2 Filed
Oct 26, 2018
Teas Extension Received
May 2, 2018
Notice Of Approval Of Extension Request E-Mailed
Apr 30, 2018
Extension 1 Granted
Apr 30, 2018
Extension 1 Filed
Apr 30, 2018
Teas Extension Received
Nov 28, 2017
Noa E-Mailed - Sou Required From Applicant
Oct 15, 2017
Extension Of Time To Oppose Process - Terminated
Jul 15, 2017
Changes/Corrections After Pub Approval Entered
Jul 12, 2017
Assigned To Petition Staff
Jul 7, 2017
Teas Post Publication Amendment Received
Jun 28, 2017
Extension Of Time To Oppose Received
Jun 6, 2017
Official Gazette Publication Confirmation E-Mailed
Jun 6, 2017
Published For Opposition
May 17, 2017
Notification Of Notice Of Publication E-Mailed
Apr 27, 2017
Approved For Pub - Principal Register
Apr 24, 2017
Assigned To Examiner
Mar 24, 2017
New Application Office Supplied Data Entered In Tram
Mar 24, 2017
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24